Emerging role of ubiquitination/deubiquitination modification of PD-1/PD-L1 in cancer immunotherapy

Peng Ding; Zhiqiang Ma; Yizeng Fan; Yingtong Feng; Changjian Shao; Minghong Pan; Yimeng Zhang; Di Huang; Jing Han; Yi Hu; Xiaolong Yan

doi:10.1016/j.gendis.2022.01.002

您当前的位置：

首页 >

文章列表页 >

Emerging role of ubiquitination/deubiquitination modification of PD-1/PD-L1 in cancer immunotherapy

Review article | 更新时间：2023-08-29

- Emerging role of ubiquitination/deubiquitination modification of PD-1/PD-L1 in cancer immunotherapy
- Emerging role of ubiquitination/deubiquitination modification of PD-1/PD-L1 in cancer immunotherapy
- Genes & Diseases 2023年10卷第3期
- 作者机构：
  
  1. Department of Urology, The First Affiliated Hospital of Xi'an Jiaotong University,Shaanxi,Xi'an,China,710061
  2. Department of Thoracic Surgery, Tangdu Hospital, The Air Force Military Medical University,Shaanxi,Xi'an,China,710038
  3. Department of Ophthalmology, Tangdu Hospital, The Air Force Medical University,Shaanxi,Xi'an,China,710038
  4. Department of Medical Oncology, Senior Department of Oncology, The Fifth Medical Center of PLA General Hospital,Beijing,China,100853
- 作者简介：
- 基金信息：
- DOI：10.1016/j.gendis.2022.01.002
  中图分类号：
- 纸质出版日期：2023，
  
  网络出版日期：2023-5-1，
扫描看全文
Peng Ding, Zhiqiang Ma, Yizeng Fan, 等. Emerging role of ubiquitination/deubiquitination modification of PD-1/PD-L1 in cancer immunotherapy[J]. Genes & Diseases, 2023,10(3).

Peng Ding, Zhiqiang Ma, Yizeng Fan, et al. Emerging role of ubiquitination/deubiquitination modification of PD-1/PD-L1 in cancer immunotherapy[J]. Genes & Diseases, 2023,10(3).
Peng Ding, Zhiqiang Ma, Yizeng Fan, 等. Emerging role of ubiquitination/deubiquitination modification of PD-1/PD-L1 in cancer immunotherapy[J]. Genes & Diseases, 2023,10(3). DOI： 10.1016/j.gendis.2022.01.002.

Peng Ding, Zhiqiang Ma, Yizeng Fan, et al. Emerging role of ubiquitination/deubiquitination modification of PD-1/PD-L1 in cancer immunotherapy[J]. Genes & Diseases, 2023,10(3). DOI： 10.1016/j.gendis.2022.01.002.

摘要

Abstract

members of the immune checkpoint family

PD-1 and its ligand PD-L1 play critical roles in maintaining the balance between autoimmunity and tolerance. The interaction of PD-1/PD-L1 is also involved in tumor evasion inside the tumor microenvironment

caused by reduced T cell activation

proliferation

cytotoxic secretion

and survival. Previous research has shown that the expression level of PD-1/PD-L1 may be regulated by ubiquitin-mediated proteasome degradation

which is an important mode of post-translational modification (PTM). PD-1/PD-L1 ubiquitin modification research in tumor immunotherapy is the subject of the present review

which aims to assess the most recent developments in this area. We offer a short explanation of PD-1/PD-L1 as well as some basic background information on the UPS system and discuss many routes that target E3s and DUBs

respectively

in the regulation of PD-1/PD-L1 in tumor immunotherapy. In addition

we offer numerous innovative prospective research areas for the future

as well as novel immunotherapy concepts and ideas. Taken together

the information compiled herein should serve as a comprehensive repository of information about tumor immunotherapy that is currently available

and it should be useful in the design of future studies

as well as the development of potential targets and strategies for future tumor immunotherapy.

关键词

Keywords

CancerDeubiquitinationImmunotherapyPD-1PD-L1Ubiquitination

references

查看原文

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

Targeting PD-1/PD-L1 in cancer immunotherapy: An effective strategy for treatment of triple-negative breast cancer (TNBC) patients

PD-L1 expression is regulated by ATP-binding of the ERBB3 pseudokinase domain

Tumor suppressor p53 cross-talks with TRIM family proteins

De novo nucleotide biosynthetic pathway and cancer

Multiple regulatory roles of the transfer RNA-derived small RNAs in cancers